Galectin Therapeutics, Inc. (GALT) Shares Surge on Positive Interim Data for Lead Candidate GR-MD-02
Shares of Galectin Therapeutics (NASDAQ: GALT) are up more than 30% this morning after delivering positive interim clinical data for its lead candidate GR-MD-02 to treat psoriasis and atopic dermatitis. The company also announced its plans to identify a strategic partnership to further develop the drug candidate for the treatment of serious skin diseases. To view the full press release, visit: http://nnw.fm/d95Ap About Galectin Therapeutics Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to…







